Barry Ticho Sells 10,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Stoke Therapeutics Stock Down 5.3 %

Shares of STOK stock traded down $0.64 on Tuesday, hitting $11.43. The company’s stock had a trading volume of 815,806 shares, compared to its average volume of 463,215. The firm’s fifty day moving average price is $12.44 and its 200-day moving average price is $13.78. Stoke Therapeutics, Inc. has a fifty-two week low of $3.78 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $20.83.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in STOK. Lynx1 Capital Management LP increased its holdings in Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Stoke Therapeutics in the 2nd quarter valued at approximately $19,835,000. Healthcare of Ontario Pension Plan Trust Fund increased its stake in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after buying an additional 1,123,500 shares during the last quarter. Logos Global Management LP bought a new stake in Stoke Therapeutics during the second quarter worth about $14,186,000. Finally, Marshall Wace LLP increased its holdings in Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after buying an additional 982,451 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.